MARKET

SPRY

SPRY

ARS Pharms
NASDAQ
11.49
-0.16
-1.37%
After Hours: 11.94 +0.45 +3.92% 19:43 01/02 EST
OPEN
11.65
PREV CLOSE
11.65
HIGH
11.75
LOW
11.43
VOLUME
1.68M
TURNOVER
--
52 WEEK HIGH
18.90
52 WEEK LOW
6.66
MARKET CAP
1.14B
P/E (TTM)
-12.7497
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY) and Zevra Therapeutics (ZVRA)
TipRanks · 12/30/2025 11:20
ARS Pharmaceuticals announces NMPA approval for neffy 2 mg
TipRanks · 12/29/2025 13:10
National Medical Products Administration In China Grants ARS Pharmaceuticals Approval For Neffy 2 mg For Emergency Treatment Of Type 1 Allergic Reactions In Adults And Children Who Weigh 30+ KG.
Benzinga · 12/29/2025 13:05
China Approves ARS Pharmaceuticals' Neffy as First Community Use Epinephrine Product
Reuters · 12/29/2025 13:00
ARS PHARMACEUTICALS - TO RECEIVE $4 MLN REGULATORY MILESTONE AND IS ELIGIBLE TO RECEIVE UP TO $80 MLN IN SALES MILESTONES
Reuters · 12/29/2025 13:00
Weekly Report: what happened at SPRY last week (1222-1226)?
Weekly Report · 12/29/2025 10:34
Weekly Report: what happened at SPRY last week (1215-1219)?
Weekly Report · 12/22/2025 10:34
Weekly Report: what happened at SPRY last week (1208-1212)?
Weekly Report · 12/15/2025 10:42
More
About SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Webull offers ARS Pharmaceuticals Inc stock information, including NASDAQ: SPRY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRY stock methods without spending real money on the virtual paper trading platform.